A phase I study of combination chemotherapy with gemcitabine and oral UFT for advanced non-small cell lung cancer

British Journal of Cancer

Volumn 86, Issue 11, 2002, Pages 1701-1704

  Seto, T ^a   Yoh, K ^a   Asoh, H ^b   Yamamoto, H ^c   Semba, H ^a   Ichinose, Y ^b  

^a KUMAMOTO REGIONAL MEDICAL CENTER   (Japan)

^b NATIONAL KYUSHU CANCER CENTER   (Japan)

^c ASO IIZUKA HOSPITAL   (Japan)

Author keywords

Gemcitabine; Non small cell lung cancer; Phase I study; UFT

Indexed keywords

CISPLATIN; GEMCITABINE; UFT;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE CALCULATION; DRUG EFFICACY; DRUG TOLERABILITY; EDEMA; FEMALE; HUMAN; LIVER FUNCTION; LUNG NON SMALL CELL CANCER; MALE; MAXIMUM TOLERATED DOSE; NEUTROPENIA; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; THROMBOCYTOPENIA; TREATMENT OUTCOME;

ADMINISTRATION, ORAL; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, NON-SMALL-CELL LUNG; DEOXYCYTIDINE; FEVER; HEMATOLOGIC DISEASES; HUMANS; KIDNEY; LIVER; LUNG NEOPLASMS; NAUSEA; NEOPLASM STAGING; TEGAFUR; URACIL;

EID: 0037024410     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bjc.6600337     Document Type: Article

References (25)

1. Efficacy and safety profile of gemcitabine in non-small cell lung cancer: A phase II study
2. New chemotherapeutic agents prolong survival and improve quality of life in non-small cell lung cancer: A review of the literature and future directions
3. A combination of gemcitabine and 5-fluorouracil in advanced pancreatic cancer, a report from the Italian Group for the Study of Digestive Tract Cancer (GISCAD)
4. Safety profile of gemcitabine, a novel anticancer agent in non-small cell lung cancer
5. Phase II trial of gemcitabine and UFT modulated by leucovorin in patients with advanced pancreatic carcinoma
6. A late phase II study of gemcitabine (LY 188011) against non-small cell lung cancer
7. Activity of gemcitabine in patients with non-small cell lung cancer: A multicenter, extended phase II study
8. Biochemical modulation of 5 fluorouracil/folinic acid by gemzar in colon cancer cells
9. Synthesis of 2-deoxy-2, 2-difluro-D-ribose and 2-deoxy-2, 2-D-ribofruranosyl nucleosides
10. Comparison of 5-fluorouracil pharmacokinetics in patients receiving continuous 5-fluorouracil infusion and oral uracil plus N1-(2′-Tetrahydrofuryl)-5-fluorouracil
11. A phase II trial of oral tegafur and uracil plus cisplatin in patients with inoperable nonsmall cell lung cancer
12. UFT plus cisplatin combination chemotherapy in the treatment of patients with advanced nonsmall cell lung cancer: A multiinstitutional phase II trial
13. Phase II study of UFT in patients with advanced non-small cell lung cancer
14. Phase I chemotherapy study of biochemical modulation of folinic acid and fluorouracil by gemcitabine in patients with solid tumor malignancies
15. UFT is more antineoplastic against gastric carcinoma than 5-fluorouracil, 1-(2-tetrahydrofuryl)-5-fluorouracil and 1-hexyl-carbamoyl-5-fluorouracil
16. Gemcitabine: Safety profile and efficacy in non-small cell lung cancer unaffected by age
17. Chemotherapy in non-small cell lung cancer: A meta-analysis using update data on individual patients from 52 randomized clinical trials
18. Report on nationwide pooled data and cohort investigation in UFT phase II study
19. Gemcitabine and UFT plus oral calcium folinate: Phase I study
20. Equilibrative-sensitive nucleoside transporter and its role in gemcitabine sensitivity
21. Gemcitabine: Single-agent and combination therapy in non-small cell lung cancer
22. Gemcitabine in the treatment of elderly patients with advanced non-small cell lung cancer
23. A phase II study of UFT for non-small cell lung cancer
24. Adjuvant chemotherapy after complete resection in non-small cell lung cancer
25. Effect of UFT on immune responses in mice